BluePath Capital Management’s AdvisorShares Alpha DNA Equity Sentiment ETF SENT Stock Holding History

BluePath Capital Management’s Portfolio SENT Stock Details SENT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-8,384	Closed	-$186K	–	342
2023 Q3	$186K	Buy	+8,384	New	+$197K	0.17%	103

BluePath Capital Management's SENT Position: Q4 2023 in Review

BluePath Capital Management sold out of AdvisorShares Alpha DNA Equity Sentiment ETF (SENT) in Q4 2023, closing a stake of 8,384 shares — an estimated $186K sold.

BluePath Capital Management first reported a position in SENT in Q3 2023 and held it in 1 quarter. The position peaked at $186K in Q3 2023. 0 funds tracked by Wall St. Rank hold SENT as of Q4 2023.

BluePath Capital Management reported no remaining AdvisorShares Alpha DNA Equity Sentiment ETF position as of Q4 2023 after selling out during the quarter.
BluePath Capital Management sold 8,384 AdvisorShares Alpha DNA Equity Sentiment ETF shares in Q4 2023, an estimated $186K.
BluePath Capital Management first reported a position in AdvisorShares Alpha DNA Equity Sentiment ETF in Q3 2023 and held it in 1 quarter.
BluePath Capital Management's AdvisorShares Alpha DNA Equity Sentiment ETF position peaked at $186K in Q3 2023.
0 funds tracked by Wall St. Rank held AdvisorShares Alpha DNA Equity Sentiment ETF as of Q4 2023.

Based on BluePath Capital Management's 13F filing for Q4 2023, filed 11 Jan 2024.